A5093454667- Cancer Genomics and Diagnostics
- Lymphoma Diagnosis and Treatment
- CRISPR and Genetic Engineering
- Radiomics and Machine Learning in Medical Imaging
- Lung Cancer Diagnosis and Treatment
- Viral-associated cancers and disorders
- Molecular Biology Techniques and Applications
- Head and Neck Cancer Studies
- CAR-T cell therapy research
- Single-cell and spatial transcriptomics
- Advanced biosensing and bioanalysis techniques
Broad Institute
2023-2025
Liquid biopsies enable early detection and monitoring of diseases such as cancer, but their sensitivity remains limited by the scarcity analytes cell-free DNA (cfDNA) in blood. Improvements to have primarily relied on enhancing sequencing technology ex vivo. We sought transiently augment level circulating tumor (ctDNA) a blood draw attenuating its clearance report two intravenous priming agents given 1 2 hours before recover more ctDNA. Our consist nanoparticles that act cells responsible...
Minimally invasive molecular profiling using cell-free DNA (cfDNA) is increasingly important to the management of cancer patients; however, low sensitivity remains a major limitation, particularly for brain tumor patients. Transiently attenuating cfDNA clearance from body-thereby, allowing more be sampled-has been proposed improve performance liquid biopsy diagnostics. However, there paucity clinical data on effect higher recovery. Here, we investigated impact collecting greater quantities...
Abstract Purpose While circulating tumor DNA (ctDNA) is a promising biomarker for minimal residual disease (MRD) detection in head and neck squamous cell carcinoma (HNSCC), more sensitive assays are needed accurate MRD at clinically-relevant timepoints. Ultrasensitive immediately after surgery could guide adjuvant therapy decisions, but early ctDNA dynamics poorly understood. Experimental Design We applied MAESTRO, whole-genome, tumor-informed, mutation-enrichment sequencing assay, pooled...
Tracing patient-specific tumor mutations in cell-free DNA (cfDNA) for minimal residual disease (MRD) detection is promising but challenging. Assaying more and cfDNA stands to improve MRD requires highly accurate, efficient sequencing methods proper calibration prevent false with bespoke tests.